For this reason, transplant models (such as cell-derived xenografts, patient-derived xenografts and syngeneic models) are the best choice for testing new therapies for molecular subtypes of breast cancer, such as HER2 overexpressing and triple-negative. This evidence concerns the gene ERBB2 and breast cancer.